Citizens JMP Analyst Reiterates Hold Rating on Instil Bio
ByAinvest
Friday, Aug 15, 2025 10:17 pm ET1min read
TIL--
The company's financial highlights for the quarter include a net loss of $21.4 million, up from $14.9 million in the prior year. Total operating expenses increased to $23.4 million, reflecting higher research and development costs and in-process research and development expenses. Interest income decreased to $1.0 million, while interest expense fell to $1.6 million, indicating reduced debt-related costs [2].
Instil Bio is advancing its lead product candidate, AXN-2510/IMM2510, a bispecific antibody targeting PD-L1 and VEGF in solid tumor cancers. The company is also exploring additional therapeutic candidates in diseases with significant unmet medical need. In August 2024, Axion Bio, a subsidiary of Instil Bio, in-licensed bispecific antibodies from ImmuneOnco Biopharmaceuticals, including AXN-2510/IMM2510 and AXN-27M/IMM27M [2].
Citizens JMP analyst Reni Benjamin reiterated a Hold rating on Instil Bio, with shares opening at $28.65. Benjamin has an average return of -12.6% and a 34.28% success rate on recommended stocks. The overall analyst consensus rating for Instil Bio is Moderate Buy with a $125.00 average price target. Instil Bio has a market cap of $190.7 million and a P/E ratio of -2.19 [3].
Instil Bio expects to continue incurring net losses as it invests in the development of AXN-2510/IMM2510 and explores additional in-licensing or acquisition opportunities. The company anticipates that its existing cash resources will fund operations beyond 2026, with potential extension from the sale of the Tarzana facility [2].
References:
[1] https://seekingalpha.com/news/4484597-instil-bio-non-gaap-eps-of-3_24
[2] https://www.tradingview.com/news/tradingview:7c78fb850e46b:0-instil-bio-inc-sec-10-q-report/
[3] https://www.tradingview.com/news/tradingview:7c78fb850e46b:0-instil-bio-inc-sec-10-q-report/
Citizens JMP analyst Reni Benjamin reiterated a Hold rating on Instil Bio, with shares opening at $28.65. Benjamin has an average return of -12.6% and a 34.28% success rate on recommended stocks. The overall analyst consensus rating for Instil Bio is Moderate Buy with a $125.00 average price target. Instil Bio has a market cap of $190.7M and a P/E ratio of -2.19.
Instil Bio, Inc. (NASDAQ: TIL), a biotechnology company focused on developing innovative therapies for cancer treatment, has reported its second-quarter 2025 financial results. The company reported a non-GAAP earnings per share (EPS) of -$3.24, as of June 30, 2025 [1]. This marks a significant increase from the previous year's EPS of $2.29.The company's financial highlights for the quarter include a net loss of $21.4 million, up from $14.9 million in the prior year. Total operating expenses increased to $23.4 million, reflecting higher research and development costs and in-process research and development expenses. Interest income decreased to $1.0 million, while interest expense fell to $1.6 million, indicating reduced debt-related costs [2].
Instil Bio is advancing its lead product candidate, AXN-2510/IMM2510, a bispecific antibody targeting PD-L1 and VEGF in solid tumor cancers. The company is also exploring additional therapeutic candidates in diseases with significant unmet medical need. In August 2024, Axion Bio, a subsidiary of Instil Bio, in-licensed bispecific antibodies from ImmuneOnco Biopharmaceuticals, including AXN-2510/IMM2510 and AXN-27M/IMM27M [2].
Citizens JMP analyst Reni Benjamin reiterated a Hold rating on Instil Bio, with shares opening at $28.65. Benjamin has an average return of -12.6% and a 34.28% success rate on recommended stocks. The overall analyst consensus rating for Instil Bio is Moderate Buy with a $125.00 average price target. Instil Bio has a market cap of $190.7 million and a P/E ratio of -2.19 [3].
Instil Bio expects to continue incurring net losses as it invests in the development of AXN-2510/IMM2510 and explores additional in-licensing or acquisition opportunities. The company anticipates that its existing cash resources will fund operations beyond 2026, with potential extension from the sale of the Tarzana facility [2].
References:
[1] https://seekingalpha.com/news/4484597-instil-bio-non-gaap-eps-of-3_24
[2] https://www.tradingview.com/news/tradingview:7c78fb850e46b:0-instil-bio-inc-sec-10-q-report/
[3] https://www.tradingview.com/news/tradingview:7c78fb850e46b:0-instil-bio-inc-sec-10-q-report/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet